Midkine in Plasma As a Novel Breast Cancer Marker

Overview

Journal Cancer Sci

Specialty Oncology

Date 2009 Jun 23

PMID 19538527

Citations 32

Authors

Mutsuko Ibusuki

Hiromi Fujimori

Yutaka Yamamoto

Kazutoshi Ota

Mitsuharu Ueda

Satoru Shinriki

Masahiro Taketomi

Sadatoshi Sakuma

Masanori Shinohara

Hirotaka Iwase

Yukio Ando

Affiliations

Soon will be listed here.

Abstract

Midkine, a heparin-binding growth factor, is up-regulated in many types of cancer. The aim of this study was to measure plasma midkine levels in patients with breast cancer and to assess its clinical significance. We examined plasma midkine levels in 95 healthy volunteers, 11 patients with ductal carcinoma in situ (DCIS), 111 patients with primary invasive breast cancer without distant metastasis (PIBC), and 25 patients with distant metastatic breast cancer (MBC), using an automatic immunoasssay analyzer (TOSOH AIA system). In PIBC, we studied the correlation between plasma midkine levels and clinicopathological factors. Immunoreactive midkine was detectable in the plasma of healthy volunteers, and a cut-off level of 750 pg/mL was established. In breast cancer patients, plasma midkine levels were increased above normal values. These elevated levels of midkine were seen in one (9.1%) of 11 patients with DCIS, 36 (32.4%) of 111 patients with PIBC, and 16 (64.0%) of 25 patients with MBC. Increased levels of midkine were correlated with menopausal status (P = 0.0497) and nuclear grade (P = 0.0343) in PIBC. Cancer detection rates based on midkine levels were higher than those based on three conventional markers including CA15-3 (P < 0.0001), CEA (P = 0.0077), and NCCST-439 (P < 0.0001). Detection rates of breast cancer using a combination of two conventional tumor markers (CA15-3/CEA, CA15-3/NCCST-439, or CEA/NCCST-439) with midkine is significantly higher than those using combination of three conventional tumor markers. Midkine may be a useful novel tumor marker for detection of breast cancer, superior to conventional tumor markers.

Citing Articles

Midkine Serum Levels in Inflammatory and Non-Inflammatory Dilated Cardiomyopathy.

Grabmaier U, Ferraro B, Lehnert K, Petersmann A, Felix S, Weckbach L Biomedicines. 2025; 13(2).

PMID: 40002917 PMC: 11852821. DOI: 10.3390/biomedicines13020504.

Midkine as a driver of age-related changes and increase in mammary tumorigenesis.

Yan P, Jimenez E, Li Z, Bui T, Seehawer M, Nishida J Cancer Cell. 2024; 42(11):1936-1954.e9.

PMID: 39366375 PMC: 11560576. DOI: 10.1016/j.ccell.2024.09.002.

Midkine: A Cancer Biomarker Candidate and Innovative Therapeutic Approaches.

Yildirim B, Kulak K, Bilir A Eur J Breast Health. 2024; 20(3):167-177.

PMID: 39257008 PMC: 11589292. DOI: 10.4274/ejbh.galenos.2024.2024-4-7.

Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting.

Saikia M, Cheung N, Singh A, Kapoor V Int J Mol Sci. 2023; 24(10).

PMID: 37240085 PMC: 10218550. DOI: 10.3390/ijms24108739.

Anticancer Effects of New Ceramides Isolated from the Red Sea Red Algae   in a Model of Ehrlich Ascites Carcinoma: LC-HRMS Analysis Profile and Molecular Modeling.

Elhady S, Habib E, Abdelhameed R, Goda M, Hazem R, Mehanna E Mar Drugs. 2022; 20(1).

PMID: 35049918 PMC: 8778197. DOI: 10.3390/md20010063.

References

Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K . Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2007; 110(3):465-75. DOI: 10.1007/s10549-007-9742-1. View

Obata Y, Kikuchi S, Lin Y, Yagyu K, Muramatsu T, Kumai H . Serum midkine concentrations and gastric cancer. Cancer Sci. 2005; 96(1):54-6. PMC: 11158683. DOI: 10.1111/j.1349-7006.2005.00001.x. View

Muramatsu T . Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002; 132(3):359-71. DOI: 10.1093/oxfordjournals.jbchem.a003231. View

Trudeau M, Pritchard K, Chapman J, Hanna W, Kahn H, Murray D . Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat. 2005; 89(1):35-45. DOI: 10.1007/s10549-004-1368-y. View

Imai S, Kaksonen M, Raulo E, Kinnunen T, Fages C, Meng X . Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J Cell Biol. 1998; 143(4):1113-28. PMC: 2132954. DOI: 10.1083/jcb.143.4.1113. View

Takei Y, Kadomatsu K, Goto T, Muramatsu T . Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer. 2006; 107(4):864-73. DOI: 10.1002/cncr.22068. View

Kato M, Shinozawa T, Kato S, Awaya A, Terada T . Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med. 2000; 124(6):848-52. DOI: 10.5858/2000-124-0848-IMEIHC. View

Wang Q, Huang Y, Ni Y, Wang H, Hou Y . siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization. J Biomed Sci. 2007; 14(6):783-95. DOI: 10.1007/s11373-007-9192-0. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21(17):3357-65. DOI: 10.1200/JCO.2003.04.576. View

10.

Kuroi K, Toi M . Circulating angiogenesis regulators in cancer patients. Int J Biol Markers. 2001; 16(1):5-26. DOI: 10.1177/172460080101600102. View

11.

Qi M, Ikematsu S, Maeda N, Sakuma S, Noda M, Muramatsu T . Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem. 2001; 276(19):15868-75. DOI: 10.1074/jbc.m005911200. View

12.

Sakurai H, Bush K, Nigam S . Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis. Development. 2001; 128(17):3283-93. DOI: 10.1242/dev.128.17.3283. View

13.

Ye C, Qi M, Fan Q, Ito K, Akiyama S, Kasai Y . Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer. 1999; 79(1):179-84. PMC: 2362182. DOI: 10.1038/sj.bjc.6690030. View

14.

Choudhuri R, Zhang H, Donnini S, Ziche M, Bicknell R . An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997; 57(9):1814-9. View

15.

Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K . Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003; 94(7):628-32. PMC: 11160222. DOI: 10.1111/j.1349-7006.2003.tb01494.x. View

16.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

17.

Moon H, Park W, Sung S, Choi E, Chung H, Woo B . Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Oncol. 2003; 88(3):289-97. DOI: 10.1016/s0090-8258(02)00070-7. View

18.

Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T . Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995; 86(7):655-61. PMC: 5920887. DOI: 10.1111/j.1349-7006.1995.tb02449.x. View

19.

Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H . Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008; 99(4):655-62. PMC: 2527829. DOI: 10.1038/sj.bjc.6604539. View

20.

Mashour G, Ratner N, Khan G, Wang H, Martuza R, Kurtz A . The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001; 20(1):97-105. DOI: 10.1038/sj.onc.1204026. View